News

August 28, 2014 — Medtronic Inc. announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva CRT-P, for indicated patients with...

Biotronik announced the first implantations worldwide of its new ICD and CRT-D series (implantable cardioverter-defibrillators and cardiac resynchronization therapy defibrillators).

Medtronic Viva Quad XT CRT-D Adaptiv CRT

August 11, 2014 — Medtronic announced it has received U.S. Food and Drug Administration (FDA) approval for the Attain Performa model 4298 quadripolar lead, and the Viva Quad XT and Viva Quad S...

May 14, 2014 — Data presented during Heart Rhythm 2014 found the use of quadripolar leads reduced the number of hospitalizations by 53 percent when compared to the non-quadripolar group. This...

Medtronic announced the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization therapy-pacemakers and -...

ICD, MADIT-CRT trial, long-term followup, ACC.14

Patients in mild heart failure who receive a cardiac resynchronization therapy defibrillator (CRT-D) device may live longer than those implanted with a traditional implantable...

Boston Scientific Ingevity Leads MRI Systems Pacemakers CRT EP Lab

Boston Scientific Corp. received CE marking and launched in Europe the Ingevity family of magnetic resonance imaging...

Boston scientific autogen x4 crt-d crt ICD heart failure cardiac

Boston Scientific Corp. has received CE mark approval of its X4 line of quadripolar ...

EP lab crt icd boston scientific europace

An independent study from the University of Pittsburgh Medical Center, published online this week in EP EuroPace, showed significant differences in battery longevity...

cardioverter defibrillator cardiac resynchronization therapy biotronik ilesto DX

The U.S. Food and Drug Administration (FDA) approved Biotronik’s Ilesto family of implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillators (ICD/CRT-D devices)....

Medtronic Inc. announced clinical trial results showing that heart failure patients treated with its AdaptivCRT feature experienced a nearly 50 percent reduction in atrial fibrillation (...

CardioMEMs

The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee will review two new technologies to help treat heart failure (HF) Oct. 8-9,...

Researchers announced this week that an attempt to expand cardiac resynchronization therapy (CRT) to include more patients with heart failure has failed and an international clinical trial ended...

Nanostim, leadless pacemaker

There have been several advances in electrophysiology (EP) technologies this past year, many of which were highlighted during the Heart Rhythm Society (HRS) 2013 scientific sessions earlier this...

July 25, 2013 — The 2013 ESC (European Society of Cardiology) Guidelines on Cardiac Pacing and Cardiac Resynchronization Therapy, developed in collaboration with the European Heart Rhythm...

June 28, 2013 — St. Jude Medical Inc. announced CE mark approval of its next-generation quadripolar device, the Quadra Assura MP cardiac resynchronization therapy defibrillator (CRT-D).

Medtronic Inc. announced new data demonstrating that simultaneously pacing the lower chambers of the heart, or biventricular (BiV) pacing with a cardiac resynchronization therapy (CRT) device,...

The American College of Cardiology and the American Heart Association released an expanded clinical practice guideline for the management of patients with heart failure, updating definitions and...

The incremental mortality in implantable pacemaker and defibrillator recipients who experience a device infection, compared to patients without device infection, is substantial and persists for at...